News, views, and coverage of important topics and discussions from oncology conferences and events.
[widgetkit id="2" name="CC Highlights"]
Combinations of novel immunotherapy agents provide benefits over standard-of-care therapy in NSCLC and malignant pleural mesothelioma.
After more than 4 years of follow-up, patients with advanced NSCLC treated with nivolumab plus ipilimumab maintained overall survival rates.
Nivolumab plus ipilimumab combined with 2 cycles of chemotherapy for the treatment of advanced NSCLC demonstrates durable efficacy compared with 4 cycles of chemotherapy alone in a 2-year follow-up study.
Durvalumab plus standard-of-care chemotherapy and durvalumab with tremelimumab plus standard-of-care chemotherapy were both associated with better progression-free survival compared with standard-of-care chemotherapy alone in the treatment of metastatic NSCLC.
Dual immune checkpoint inhibitor therapy provides significant and durable survival benefits over chemotherapy as first-line treatment in metastatic NSCLC.
Every year, researchers and clinicians report on exciting advancements in the diagnosis and treatment of cancer. In 2021, despite the COVID-19 pandemic, developments in the management of lung cancer continue to be important and intriguing.
In patients with non–small-cell lung cancer (NSCLC) that involves the central nervous system and who lack genetic rearrangements or tumor targets, DM-CHOC-PEN, a bis-alkylator of DNA, has produced long-term objective responses with manageable toxicities.
Therapeutic outcomes based on plasma-based comprehensive genomic profiling are comparable to published tissue-based targeted therapy clinical outcomes in non–small-cell lung cancer (NSCLC).
Overall survival is longer for patients with advanced non–small-cell lung cancer who received atezolizumab and had immune-related adverse events versus patients who received atezolizumab and did not have immune-related adverse events.
Chemotherapy plus immunotherapy (IO) may improve efficacy outcomes over IO alone in most patients with advanced non–small-cell lung cancer (NSCLC) and programmed death ligand 1 (PD-L1) scores between 1% and 49%.